Court of Justice of the European Union · Judgment
C‑493/12Eli Lilly and Company Ltd v Human Genome Sciences Inc
- Decided
- 2013-12-12
- ECLI
- ECLI:EU:C:2013:835
- CELEX
- 62012CJ0493
- Finality
- Final, the decision cannot be appealed
The court's own keywords
Medicinal products for human use — Supplementary protection certificate — Regulation (EC) No 469/2009 — Article 3 — Conditions for obtaining such a certificate — Concept of a ‘product protected by a basic patent in force’ — Criteria — Wording of the claims of the basic patent — Precision and specificity — Functional definition of an active ingredient — Structural definition of an active ingredient — European Patent Convention.
Interprets
Read from EU:s publikationsbyrå, Cellar (EUR-Lex och CURIA) on 2026-08-22.
The row repeats what the source states. It is not a summary, not a conclusion about any single case and not legal advice.
Verifiable trust signals
- Six fixed blocks, one source per line
- No sentence written by a language model
- Engine version and read date on every answer
- No customer data, no documents, no advice
- Model card and audit published under the EU AI Act